Click Here for 5% Off Your First Aladdin Purchase!

UNC569 - 98%, high purity , CAS No.1350547-65-7

  • ≥98%
Item Number
U646282
Grouped product items
SKUSizeAvailabilityPrice Qty
U646282-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$110.90
U646282-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$180.90
U646282-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$400.90
U646282-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$650.90

Basic Description

Specifications & Purity≥98%
Biochemical and Physiological MechanismsUNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC 50 of 2.9 nM and a K i of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC 50 s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblasti
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
Product Description

UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC 50 of 2.9 nM and a K i of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC 50 s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research

In Vitro

UNC569 (24 hours) induces apoptosis in ALL cell lines, and increases the levels of cleaved Caspase 3 and cleaved PARP. UNC569 (1 µM; 1.5 hours) treatment effectively inhibit the activation of Mer and downstream signaling, including the PI3K/AKT and MAPK/ERK pathways. UNC569 (1 hour) inhibits Mer phosphorylation levels with IC50 values of 141 nM and 193 nM in human B-ALL (acute lymphoblastic leukemia) 697 and Jurkat cell lines, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: 697 and Jurkat cells Concentration: 0.4 µM, 0.8 µM, 1 µM, 1.2 µM, 1.4 µM, 1.6 µM, 1.8 µM, 2 µM Incubation Time: 24 hours Result: Induced apoptosis in ALL cell lines. Western Blot AnalysisCell Line: 697 and Jurkat cells Concentration: 1 µM Incubation Time: 1.5 hours Result: Inhibited Mer activation and downstream signaling through ERK1/2 and AKT.

In Vivo

The in vivo pharmacokinetic properties of UNC569 (3 mg/kg) are also assessed in mice via both intravenous (IV) and oral (PO) administration. UNC569 has low systemic clearance (19.5 mL/min/kg), high volume of distribution (V ss of 5.83 L/kg), and good oral bioavailability (57%) . Leukemic zebrafish are treated continuously for 2 weeks by immersion in 4 µM UNC569. the result shows that UNC569 induces more than 50% reduction in tumor burden compared with vehicle- and mock-treated fish. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:IC50: 2.9 nM (Mer), 37 nM (Axl), 48 nM (Tyro3), Ki: 4.3 nM (Mer)

Associated Targets

RET Tclin Proto-oncogene tyrosine-protein kinase receptor Ret 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TYRO3 Tchem Tyrosine-protein kinase receptor TYRO3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FLT3 Tclin Receptor-type tyrosine-protein kinase FLT3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MERTK Tchem Tyrosine-protein kinase Mer 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAPKAPK2 Tchem MAP kinase-activated protein kinase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AXL Tchem Tyrosine-protein kinase receptor UFO 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 1-[(4-aminocyclohexyl)methyl]-N-butyl-3-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-6-amine
INCHI InChI=1S/C22H29FN6/c1-2-3-12-25-22-26-13-19-20(16-6-8-17(23)9-7-16)28-29(21(19)27-22)14-15-4-10-18(24)11-5-15/h6-9,13,15,18H,2-5,10-12,14,24H2,1H3,(H,25,26,27)
InChi Key OGEBRHQLRGFBNV-UHFFFAOYSA-N
Canonical SMILES CCCCNC1=NC=C2C(=NN(C2=N1)CC3CCC(CC3)N)C4=CC=C(C=C4)F
Isomeric SMILES CCCCNC1=NC=C2C(=NN(C2=N1)CC3CCC(CC3)N)C4=CC=C(C=C4)F
PubChem CID 53355503
MeSH Entry Terms UNC569
Molecular Weight 396.50

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

SolubilityDMSO : 31.25 mg/mL (78.81 mM; Need ultrasonic)

Related Documents

Solution Calculators